Antibiotics Market Analysis, Size, Trends - Segmented by Product Type (Cephalosporins, Penicillins, Fluroquinilones, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides), by Spectrum and Geography - Growth, and Forecast (2018 - 2023)

Antibiotics Market Analysis, Size, Trends - Segmented by Product Type (Cephalosporins, Penicillins, Fluroquinilones, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides), by Spectrum and Geography - Growth, and Forecast (2018 - 2023)

The antibiotics market was valued at about USD 40,866 million in 2017, which is estimated to register a CAGR of 4.7%, over the forecast period, 2018 to 2023. Antibiotic medicines are among the most prescribed courses worldwide, in fighting bacterial infections, primarily in the outpatient settings. The market is primarily driven by the emergence and wide distribution of anti-MRSA drugs, along with a growing demand for generic drugs. As per the geographical analysis, the North American region possess several factors, such as well-developed healthcare infrastructure, better insurance coverage, and high consumption rate of antibiotics, which helps in maintaining dominance in the region.

Development and Growing Demand of Generic Drugs to Boost the Antibiotics Market

The global demand for antibiotics has grown significantly over the past two decades. There are a range of global pharmaceutical companies, as well as smaller firms in countries, such as India that plays a high role in domestic regions in the production of generic drugs. Most of the antibiotic drugs are cheap, off-patent generic medicines which are easily and widely affordable, especially among the low income and lower-middle-income countries. In addition, the generic industries play a major role in the cost reduction of pharmaceutical drugs, which increase the overall higher availability and consumption, worldwide. As per the WebMD, almost 80% of the prescription drugs that are sold are generics. Some major generic players are Teva, Mylan, Novartis (Sandoz), and Cipla, among others. The above factors, along with others, help generic drugs business to contribute to the growth of the antibiotics market.Other factors contributing to the antibiotics market are an emergence of anti-Methicillin-resistant Staphylococcus aureus (MRSA) drugs to combat the increasing resistance against antibiotic resistance and vulnerable aging population.

Increasing Resistance against Antibiotics Limits the Growth of Antibiotics Market

According to the World Health Organization (WHO), antibiotic resistance is among the major global threats to global health, food security, and development. This, in turn, leads to higher medical costs, prolonged hospital stays, and increased mortality. With a growing number of infections such as pneumonia, tuberculosis, gonorrhea, and salmonellosis, the drug resistance significantly affects the treatment of infections. According to a recent article published in Proceedings of the National Academy of Sciences, the developed nations consumes antibiotics twice a rate than the low- and middle-income countries. As a result, the increasing resistance against antibiotics is among the major restraints for the antibiotics market.Other factors limiting the growth of this market are lesser companies in active R&D for antibiotics, the time taken for the regulatory approval, and the increase in drug approval costs.

Market Segmentation Insights for the Antibiotics Market

In product type segmentation, cephalosporins are expected to occupy the largest share by revenue, globally, with about 25% share in 2017. These beta-lactam antibiotics that inhibit the synthesis of peptidoglycan, are most frequently prescribed antibiotics globally. It is used for a wide variety of bacterial infections such as ear, skin, kidney, bone, mouth, and others. The fifth generation is highly advanced where multiple companies through technology advancements are targeting resistance against a broad range of infections and their complexities.In the spectrum segment, a large focus is on broad-spectrum antibiotics which share the major part of the revenue and estimated to grow consistently, over the forecast period. The companies are targeting gram-negative, gram-positive, and anaerobic bacteria, via broad-spectrum antibiotics. In addition, since the antibiotic resistance is epidemic, this segment plays a major role in the area of unmet medical needs with increasing support from government approval authorities.

Asia-Pacific Expected to Provide Large Growth Opportunities Over the Forecast Period

Asia-Pacific has observed a trend of increasing antibiotic consumption in countries, such as China and India, having diversified patient population where there is a continuous rise in demand for generic antibiotics. The third and fourth generation broad-spectrum antibiotics, under cephalosporins are consumed heavily in several countries across Southeast Asian countries. These countries are rich with preparations on preclinical and early phase drug candidates in their research laboratories. In countries like Singapore, the government has recently announced a national strategic plan to tackle the antimicrobial resistance. In India, a 5-year strategy for antibiotic resistance was initiated by the Chennai Declaration group. The campaigns and strategic plans are among the national level programs, which raises the awareness in the society and helps private organizations, as well as multinational players to expand in developing countries. Thus, Asia-Pacific countries are expected to generate high opportunities for the growth of the antibiotics market.

Key Developments in the Market

- June 2018 - Acurx Pharmaceuticals announced that the US Food and Drug Administration (FDA) designated ACX-362E, lead antibiotic candidate, as a Qualified Infectious Disease Product (QIDP) with Clostridium difficile infection (CDI).
- June 2018 - AmpliPhi Biosciences Corporation released a poster presentation of AB-PA01 bacteriophage therapy, on a successful case study of a patient with cystic fibrosis.
Oct 2018- Novartis entered into a licensing and equity agreement with Boston Pharmaceuticals to develop three novel anti-infective drug candidates against antibiotic-resistant Gram-negative infections.

Major Players -GlaxoSmithKline PLC, Merck & Co. Inc, Pfizer Inc, Novartis AG, Sanofi SA, among others.

Reasons to Purchase Antibiotics Market Report

- Current and future of antibiotics market outlook in the developed and emerging markets
- Analysis of various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3 months analyst support, along with the Market Estimate sheet (in Excel)

Customize Antibiotics Market Report

- This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Antibiotics Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Antibiotics Market Drivers
6.1.1 Emergence of Anti-MRSA/VRE Drugs
6.1.2 Development of Generic Drugs
6.1.3 Vulnerable Aging Population
6.2 Antibiotics Market Restraints
6.2.1 Antibiotic Resistance
6.2.2 Fewer Companies Involved in Active Research
6.2.3 Time Taken for Regulatory Approval
6.3 Antibiotics Market Opportunities
6.4 Antibiotics Market Key Challenges
7. Market Segmentation
7.1 Antibiotics Market By Product Type
7.1.1 Cephalosporins
7.1.2 Penicillins
7.1.3 Fluroquinilones
7.1.4 Macrolides
7.1.5 Carbapenems
7.1.6 Aminoglycosides
7.1.7 Sulfonamides
7.1.8 Others
7.2 Antibiotics Market By Spectrum
7.2.1 Broad-Spectrum Antibiotics
7.2.2 Narrow-Spectrum Antibiotics
7.3 Antibiotics Market By Geography
7.3.1 North America Antibiotics Market Size (2018 - 2023) United States Antibiotics Market Size (2018 - 2023) Canada Antibiotics Market Size (2018 - 2023) Mexico Antibiotics Market Size (2018 - 2023)
7.3.2 Europe Antibiotics Market Size (2018 - 2023) France Antibiotics Market Size (2018 - 2023) Germany Antibiotics Market Size (2018 - 2023) United Kingdom Antibiotics Market Size (2018 - 2023) Italy Antibiotics Market Size (2018 - 2023) Spain Antibiotics Market Size (2018 - 2023) Rest of Europe
7.3.3 Asia-Pacific Antibiotics Market Size (2018 - 2023) China Antibiotics Market Size (2018 - 2023) Japan Antibiotics Market Size (2018 - 2023) India Antibiotics Market Size (2018 - 2023) Australia Antibiotics Market Size (2018 - 2023) South Korea Antibiotics Market Size (2018 - 2023) Rest of Asia-Pacific
7.3.4 Middle East & Africa Antibiotics Market Size (2018 - 2023) GCC Antibiotics Market Size (2018 - 2023) South Africa Antibiotics Market Size (2018 - 2023) Rest of Middle East & Africa
7.3.5 South America Antibiotics Market Size (2018 - 2023) Brazil Antibiotics Market Size (2018 - 2023) Argentina Antibiotics Market Size (2018 - 2023) Rest of South America
8. Antibiotics Market Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Antibiotics Market Major Players
9.1 GlaxoSmithKline Plc
9.2 Johnson & Johnson Inc
9.3 Merck & Co. Inc
9.4 Pfizer Inc.
9.5 Bayer Healthcare AG
9.6 Novartis AG
9.7 Sanofi SA
9.8 Abbott Laboratories
9.9 Roche Holding AG
**List Not Exhaustive
10. Future of the Antibiotics Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook